Yaben Chemical announced that the 14th meeting of the sixth board of directors of the company reviewed and approved a plan to issue A-shares to specific targets in 2026. It is proposed to issue shares to no more than 35 specific investors, with a total capital of no more than $841 million. After deducting issuance fees, it will be used for: 36 million yuan for a pilot project with an annual output of 35 tons of high-end pharmaceutical intermediates, 134 million yuan for a new project with an annual output of 2019 tons of APIs and intermediates, 280 million yuan for a new project with an annual output of 50 tons of reglitine and 2 tons of SERD inhibitors, 200 million yuan for R&D center construction projects, and additional working capital of 160 million yuan.

Yaben Chemical announced that the 14th meeting of the sixth board of directors of the company reviewed and approved a plan to issue A-shares to specific targets in 2026. It is proposed to issue shares to no more than 35 specific investors, with a total capital of no more than $841 million. After deducting issuance fees, it will be used for: 36 million yuan for a pilot project with an annual output of 35 tons of high-end pharmaceutical intermediates, 134 million yuan for a new project with an annual output of 2019 tons of APIs and intermediates, 280 million yuan for a new project with an annual output of 50 tons of reglitine and 2 tons of SERD inhibitors, 200 million yuan for R&D center construction projects, and additional working capital of 160 million yuan.